May 8, 2015
The medication was so effective in mantle cell lymphoma, an aggressive, incurable cancer, that the Food and Drug Administration named ibrutinib a "breakthrough" drug. The unprecedented response — 68 percent of patients went into partial or complete remission when they took it — gained the agent accelerated approval last November.But the disease remains a challenge. Researchers, including those at Weill Cornell Medical College who participated in the ibrutinib clinical trial, found that lymphoma cells in the majority of patients who were taking the drug on its own became resistant to it,...
April 21, 2015
Weill Cornell Medical College investigators, led by Drs. Mark A. Rubin, Sandra J. Shin and Juan Miguel Mosquera, tried to validate a previously reported molecular finding on triple negative breast cancer that many hoped would lead to targeted treatments for the aggressive disease. Instead, they discovered that the findings were limited to a single patient and could not be applied to further clinical work.
April 15, 2015
Dr. Mark A. Rubin published a comment in Nature that highlights the need to connect genomic and clinical data.
March 23, 2015
Welcome to Michael Kluk, MD, PhD, who has been appointed as Director of Molecular and Genomic Pathology!
Michael Kluk, MD, PhDDirector, Molecular and Genomic Pathology
February 10, 2015
Dr. Stephen Master graduated from the University of Pennsylvania combined M.D./Ph.D. program in 2002. Subsequently, he completed residency training in Clinical Pathology, including serving as Chief Resident in Clinical Pathology, at the Hospital of the University of Pennsylvania in 2004. He served as a Research Associate in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania in 2004-2005. He was appointed Assistant Professor of Pathology and Laboratory Medicine at that institution in 2005 and has served in that capacity since then.
January 23, 2015
A team of researchers has sequenced the genome of Classical Hodgkin lymphoma, illuminating exactly which proteins are altered in individual patients. The findings could pave the way to delivering personalized treatments and more effective options, since current treatments can be toxic and don’t work for close to 20 percent of patients diagnosed with the disease.
Ethel Cesarman, MD, PhDProfessor of Pathology and Laboratory Medicine
January 23, 2015
The Cancer Gene Mutation Panel- 50 (CGMP-50) test is a Targeted Next Generation Sequencing (NGS) assay that is used to interrogate the variant status of 50 cancer-related genes in solid tumors including but not limited to Colorectal, Lung, Brain, Ovarian, Thyroid, Breast cancers and Melanomas. The assay is performed on the Ion Torrent Personal Genome Machine (PGM) platform.
November 6, 2014
Congratulations to Dr. Giorgio Inghirami, Professor of Pathology and Laboratory Medicine, to the newly created role of Director of the Institutional Biobank!
October 22, 2014
"Organoid Cultures Derived from Patients with Advanced Prostate Cancer," co-first authored by Dr. Andrea Sboner, has been featured on the Weill Cornell Medical College website. Read the full article here.
October 21, 2014
The British Medical Association awarded Dr. Knowles’ book, Knowles’ Neoplastic Hematopathology Third Ed., first prize for the best Pathology book of the year.